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Abstract 
 
Plasminogen activator inhibitor type-1 (PAI-1) is a member of the serine protease inhibitor 
(serpin) family. PAI-1 is involved in the regulation of fibrinolysis, which is the breakdown of 
blood clots. PAI-1 inhibits serine proteases tissue-type plasminogen activator (tPA) and 
urokinase-type plasminogen activator (uPA), which are key factors in fibrinolysis. Excess levels 
of PAI-1 have also been shown to increase the risk of diabetes, stroke, and atherosclerosis, as 
well as tumor development. Previous attempts at synthesizing a practical drug for the regulation 
of PAI-1 have not been successful; therefore, it has been the purpose of this study to further 
advance progress in this area. Working from a lead molecule derived from a high-throughput 
library screen, different derivatives were synthesized and tested for anti-PAI-1 activity. By 
studying the relationships between different aromatic substitutions, our goal was to discover a 
connection between these substitutions and more potent inhibition of PAI-1. This study discusses 
the synthesis and impact of the different derivatives of those small molecules on PAI-1 
inhibition.  
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Chapter I 
I-1: Plasminogen Activator Inhibitor-1: Interactions and Diseases 
 Plasminogen activator inhibitor-1 (PAI-1) is a protein present in all mammals, including 
humans. PAI-1 is present in low amounts in the body, but even in such small concentrations, it 
has a large impact on human health. PAI-1 has various roles in the body, but the primary one is 
to regulate fibrinolysis. Fibrinolysis occurs via the conversion of plasminogen, an inactive 
protein, into the enzyme plasmin, which then degrades fibrin clots into products able to be used 
by the body in other functions. When PAI-1 binds with tissue-type plasminogen activator (tPA) 
and urokinase-type plasminogen activator (uPA), it inhibits the conversion of plasminogen (a 
zymogen) into active plasmin, thus regulating the cycle. Therefore, it is understood that an 
excess of PAI-1 can lead to hypofibrinolysis: an increase in the level of blood clots.1-3 This has 
led to a number of studies that have connected PAI-1 to various blood related diseases such as 
thromboembolism, coronary artery disease, sepsis, myocardial infarction, as well as cancer, 
atherosclerosis, and type 2 diabetes. 1-3  
 This is immediately concerning because it shows that PAI-1 is capable of holding 
multiple different pathological roles, based on its connection to each disease. When an excess of 
PAI-1 is present and hypofibrinolysis occurs, it is thought that there is a parallel increase in the 
pathogenesis of atherosclerosis by exposing arteries to chronic thrombosis.3 With the 
acceleration of angiogenesis brought on by PAI-1, cancer is able to progress.4-10 PAI-1 has also 
been seen to have a relationship with increased levels of amyloid beta in the brain. Amyloid beta 
has been known to increase amyloid plaques, thought to cause Alzheimer’s disease.11 Studies 
have shown that removing the PAI-1 gene can lead to increased levels of plasmin and tPA, and 
decreased levels of amyloid beta in the brain.12  
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 As previously stated, PAI-1 has been linked to various blood diseases; specifically, in 
high concentrations PAI-1 was found to be linked to coronary artery disease as well as 
atherosclerosis and myocardial infarction. With PAI-1 in abundance, the balance of fibrin to 
fibrin degradation products is severely skewed. This causes plaque buildup and poor regulation 
in the arteries of the heart, which in turn can cause hardening of these blood vessels and leads to 
more disastrous results, such as heart failure.13,14  
 In a study where mice were engineered to produce no PAI-1, many of these diseases were 
studied. It was found that prognosis of atherosclerosis, thrombosis, and diabetes-induced 
nephrosis was noticeably improved. This not only showed that PAI-1 is a factor in these 
diseases, but also that reducing PAI-1’s levels may aid in preventing them significantly.15-19 A 
similar study conducted with PAI-1 deficiency was shown to prevent obesity as well as a 
development of resistance to insulin.3 Other studies have suggested that a deficiency of PAI-1 
can aid in the prevention of excess fibrin accumulation and bleomycin-induced fibrosis in the 
lungs.20 In contrast, abnormally low levels of PAI-1 also have their drawbacks. PAI-1 deficiency 
has been found to be associated with spontaneously developed age-dependent cardiac-selective 
fibrosis.21  
There exist a few therapies that can aid in some of these diseases; however, many of 
these therapies (ACE inhibitors, insulin-sensitizing agents, and hormone replacements) have 
been found to indirectly boost fibrinolysis, making them not viable for long term use.22 
Therefore, it has been deemed extremely beneficial, considering PAI-1’s vast pathologically 
active network, to find regulatory agents specific for PAI-1. Considering it has been a high value 
drug target, many attempts have been made to find inhibitors of PAI-1.    
 
3 
 
I-2: PAI-1 Structure 
PAI-1 is a member of the serine protease inhibitor superfamily. While also known as 
endothelial PAI-1 or serpin E1, it is encoded by the serpine1 gene.
23 It is primarily synthesized by 
tissues of the liver, vascular and adipose; however, it is also stored and secreted by varying 
methods.24,25 In humans, PAI-1 is located at chromosome 7q21.30q22, spans about 12,200 base 
pairs and is composed of nine exons and eight introns.26,27 It is a single chain glycoprotein 
composed of 379 amino acid residues while its secondary structure is composed of 3 β-sheets, 8 
or 9 α-helices and a very important reactive center loop (RCL).28,29 A structure of PAI-1 is 
shown in Figure 1, but it is also important to know there are other forms of PAI that contribute 
to its mechanisms and activity. Most notably, PAI-1 has forms known as active, the Michaelis 
complex, covalent and cleaved. 
 
Figure 1. Structure of plasminogen activator inhibitor-130 
 Shown in Figure 1 is the active form of PAI-1. During this stage the RCL (seen above in 
red) is exposed and available for bonding to tissue-type and urokinase-type plasminogen 
activators (tPA & uPA). When this occurs, PAI-1 enters a non-covalent Michaelis complex 
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(Figure 2).31,32 This acts as an intermediate stage where one of two different pathways may 
occur, leading to either the cleaved or latent forms of PAI-1. The RCL undergoes proteolysis and 
its amino-terminal end will begin to flip 180 degrees and insert into a second location near the 
bottom of the molecule. During this time, if the protease, either tPA or uPA, is able to complete 
its catalytic cycle before insertion of the RCL, PAI-1 will take on its inactive cleaved form, while 
regenerating the active form of the protease. However, if the protease is not capable of 
completing its cycle, it will become trapped in the cleaved form of PAI-1 and become inactive.32  
 
 
 
 
 
Figure 2. Pathway and forms of PAI-130 
 
While these are the typical pathways there also exist some instances that further 
complicate PAI-1’s mode of action. It is possible that PAI-1 will spontaneously convert from its 
active form into its latent form at a half-life of approximately 1 to 2 hours. This prevents any 
interactions with active proteases and is reported to occur via conformational changes that allow 
certain strands of the molecule to slide in and out of place to allow the RCL insertion into a β-
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sheet.28,33-39 It is also possible for PAI-1 to be affected by its environment. In the presence of 
vitronectin, a glycoprotein found in the extracellular matrix of humans that promotes cell 
adhesion and motility, PAI-1 can undergo a conformational change that affects the conformation 
of the RCL.40 As seen in Figure 3, PAI-1 can bind with vitronectin specifically via the N-
terminal somatomedin-B domain on vitronectin; this stabilizes PAI-1 in its active form, 
rendering the RCL unavailable to uPA.34,41  
  
Figure 3. PAI-1 interactions with vitronectin. (a) RCL (b) Vitronectin binding location.30 
 The interactions of PAI-1 with vitronectin have been found to be able to exceed a 1:1 
stoichiometric ratio, which correlates with increased binding of the PAI-1:vitronectin complex to 
cells.42 The PAI-1:vitronectin complex is found to be twice as stable as free PAI-1, lengthening 
PAI-1’s half-life to upwards of 24 hours.39 However, the primary concern with vitronectin is that 
when it binds with PAI-1, it causes a conformational change to the binding site on PAI-1. While 
PAI-1 is bound to vitronectin, oligomers of vitronectin begin to form. During this stage tPA can 
bind to PAI-1, although this process is strained, and force vitronectin to dissociate from PAI-1. 
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When this occurs it is possible for the oligomers of vitronectin to cleave into monomers, further 
negatively affecting the cycle involving PAI-1 and its proteases.42  
 
I-3: Previous PAI-1 Inhibitors 
Since the discovery of PAI-1 there have been many attempts to develop inhibitors for it. 
Monoclonal antibodies (MA) were found to be one of the first direct inhibitors of PAI-1 activity. 
Initial MAs were found to act upon PAI-1 in several ways: impeding formation of the Michaelis 
complex that PAI-1 forms when binding with tPA/uPA, inducing behavior that cleaves PAI-1 
thereby rendering it inactive, and promoting conversion to the latent form of PAI-1 at an 
increased rate.33,37,43-46 While these MAs appeared to be strong candidates for the inhibition of 
PAI-1, they proved to fall short in bioavailability as they were quickly degraded via enzymes 
when taken orally, therefore requiring intravenous injections.  
Related studies also looked into the effect of peptides on PAI-1 activity as it was found 
that certain sequences could inhibit PAI-1 function. The peptides were able to modify the 
conformation of active PAI-1 by acting upon its reactive site loop. For example, a 14 chain 
amino acid peptide P14-P1 was shown to hasten the conversion of PAI-1 to its latent form.47 
Another peptide was remarkably found to inhibit the binding of PAI-1 to vitronectin, which 
would also accelerate conversion to the latent form, largely reducing activity.48 To much 
disappointment, however, it was concluded that peptides proved too unstable to be administered 
orally, similarly to the monoclonal antibodies. In addition, they exhibited great difficulty in 
crossing the blood-brain barrier, making them problematic in treating neurological disorders.  
 The need for a more specific and bioavailable approach lead to the development of small 
molecule inhibitors of PAI-1. There were a few attempts using previously discovered drugs or 
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molecules to combat PAI-1. Molecules that were discovered to possess some inhibitory effects 
were fibrates, herbal medicines, and butadiene derivatives. One of these fibrates, gemfibrozil, 
developed by Fujii et al. was originally shown to help lower lipid levels.49 It also was shown to 
aid in decreasing levels of PAI-1 in human hepatoma cells.49 However, other fibrates were 
actually found to increase PAI-1 levels in humans, and further, some fibrates were shown to hold 
no effect on PAI-1.49 Studies were then performed comparing different fibrates, and it was found 
that overall effectiveness greatly depended on type and concentration; however, after further 
studies, it was hypothesized that PAI-1 secretion could vary among different types of cells 
making it difficult to control, therefore requiring a better understanding of PAI-1 in order to 
develop new drugs for it specifically.49 
 It was then concluded that designing small orally effective molecules designed with PAI-
1 inhibition in mind would be the most reasonable pathway. The first small molecule inhibitors 
of PAI-1, synthesized by Xenova Limited, were diketopiperazines (DKP) derivatives XR330 (I-
1) and XR334 (I-2). Isolated from a species of Streptomyces, these were capable of inhibiting 
PAI-1’s interaction with tPA in vitro with an IC50 of 51 μM.  
                      
These molecules had limited solubility and were found to enhance fibrinolysis.50 Subsequent 
analogs XR1853, XR5082, XR5118, and XR11211 were developed which also inhibited PAI-1 
activity with IC50 values from 3.5-80 μM. These derivatives worked by encouraging the 
formation of the latent form of PAI-1, or by inhibiting the binding of PAI-1 to tPA/uPA via 
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structural changes to PAI-1. Of these compounds, XR5118 (I-3) was selected for further studies 
in vivo. XR5118 showed increased inhibition of PAI-1 and was the most selective and even 
enhanced fibrinolysis while it increased tPA activity in the plasma, indicating a possible 
treatment for thrombotic disease.51 XR11211 (I-4) was also studied further as it was also shown 
to be effective against PAI-1 with an IC50 of 0.20 μM. However, it suffered from poor 
physiochemical properties, and though there were attempts to improve it, development costs and 
likelihood of success seemed not worth the effort. These diketopiperazines all seemed to suffer 
the same fate as XR11211, as they had poor physiochemical properties and were therefore set 
aside for a new attempt at counteracting PAI-1.51-53  
                           
 One of the most analyzed small molecule inhibitors has been tiplaxtinin (I-5). With an in 
vitro IC50 value of 2.7 μM, experimentally shown to contain in vivo selective activity against 
PAI-1 in rats, as well as admirable bioselectivity and low toxicity, it appeared to be the front 
runner in small molecule inhibitors.54 Despite all of this, however, it was found that tiplaxtinin in 
the presence of vitronectin lost nearly all of its ability to inhibit PAI-1. This suggests that the 
binding site for both tiplaxtinin and vitronectin overlap.55,56 This prompted further research into 
how tiplaxtinin’s mechanism of action proceeds. Utilizing surface plasmon resonance (SPR) 
analysis it was discovered that tiplaxtinin will only bind to free PAI-1 and that once PAI-1 is 
bound to either vitronectin or becomes latent, there was no observed binding of tiplaxtinin to 
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PAI-1.56 When it is able to bind, it does so reversibly and with an IC50 of 9 to 12 μM. During this 
binding there is anti-proteolytic activity against uPA and tPA.                
 Wyeth researchers reported a number of PAI-1 inhibitors as well, of which the leading 
molecule was WAY-140312 (I-6). WAY-140312 was found to inhibit PAI-1 with an IC50 value 
of 11.7 μM, yet it also reduced thrombosis after oral administration in an in vivo vascular injury 
study. However, its bioavailability was only 29% and its half-life was extremely short.57 A later 
in vitro study in rat and human plasma found that WAY-140312 lost its activity against PAI-1 
due to the presence of vitronectin, much like tiplaxtinin did.55,58 In another study WAY-140312 
and tiplaxtinin were tested side by side against a molecule developed by Rupin and co-workers, 
S35225 (I-7), a benzothiophene derivative.58 In the presence of vitronectin in rat in vitro and in 
vivo models, it was discovered that only S35225 had activity against PAI-1. While it was 
effective intravenously in a dose dependent manner, its half-life was not beneficial for long term 
use, as it could not be orally administered.58  
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 A study performed by Bjorquist et al. attempted to look at flufenamic acid derivatives 
and found that AR-H029953XX (I-8) inhibits PAI-1 with an IC50 of 12 μM.59 After a structure-
activity relationship analysis, it was concluded that an acidic group as well as an aromatic 
structure was important in activity against PAI-1.60 Reinforcing this, the Rupin study analyzed 
benzothiophene, benzofuran, and indole-based derivatives and reported findings that also pointed 
to the importance of an acid functional group and aromatic rings in the structures of PAI-1 
inhibitors.58 The apparent downside was that the derivatives also exhibited poor solubility and 
bioavailability and, therefore, were not viable options to inhibit PAI-1 as a drug. 
 In the same vein, Wyeth later reported an oxadiazolidinedione inhibitor (I-9) against PAI-
1 with an IC50 of 0.39 μM and further expanded their research to synthesize PAI-749 (I-10).52,60 
PAI-749 was unique in that it acted on PAI-1 with a dual action mechanism. PAI-749 could bind 
to PAI-1 and block the tPA active site, thereby preventing the SDS-stable tPA/PAI-1 complex 
formation. It could also bind to PAI-1 in such a way that it would promote the plasmin-mediated 
proteolytic degradation of PAI-1. PAI-749 was found to have an IC50 value for tPA inhibition of 
0.157 μM and an IC50 value for uPA inhibition of 0.087 μM. PAI-749 was even found to be 
effective in the presence of vitronectin and appeared to bind competitively with it.61 Nonetheless 
a study performed by Lucking et al. concluded that PAI-749 could in fact not inhibit thrombus 
formation or increase fibrinolysis in vitro or ex vivo while tPA was present and, therefore, 
alongside of its poor pharmacokinetic properties, was not a viable PAI-1 inhibitor for human 
systems.62  
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Wyeth subsequently developed PAZ-417 (structure unrevealed), a molecule that was 
found to reduce Aβ levels in plasma and in the brain. It had an IC50 value against PAI-1 of 0.655 
μM and although it seemed to show promise, nothing was published on its clinical results.57  
With developing technology, another molecule was discovered through high throughput 
screening. ZK4044 (I-11) was found to be effective against PAI-1 with an IC50 value of 0.644 
μM. ZK4044 selectively binds to PAI-1 over other serpins and was found to directly inhibit 
binding of PAI-1 to tPA and uPA. Interestingly, ZK4044 was also discovered to prevent 
conversion of PAI-1 from active to latent form. However, due to its hydrophobic menthol-based 
structure, it requires optimization before further pharmacological use.24 
 
In 2007 our research group began a collaborative effort with that of Professor Daniel 
Lawrence of the University of Michigan Medical School in order to further advance the 
discovery and development of novel small molecule inhibitors of PAI-1. With the aid of a high 
throughput screen of the MicroSource SPECTRUM compound library, Lawrence and his group 
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were able to identify a total of 19 varied compounds that displayed activity against PAI-1. 
Interestingly, three of these molecules contained galloyl moieties (3,4,5-trihydroxybenzoates).56                                         
ECGC (I-12) and EGCDG (I-13), each containing three gallate groups, were found to 
have strong PAI-1 inhibitory activity. However the necessary purification and synthesis methods 
were deemed too expensive and laborious.  
                                  
 
The third, tannic acid (I-14), is a naturally occurring polyphenolic compound whose structure 
suggests potential PAI-1 activity due to its large number of gallate groups. Although it is a potent 
PAI-1 inhibitor with an IC50 value of 7 nM, it would not make a very successful drug due to its 
high molecular weight and tendency to form aggregates at micromolar concentrations. Therefore, 
a second generation of derivatives were synthesized that exhibited enhanced potency of PAI-1 
activity by 10-1000 fold over previously reported inhibitors (Figure 4).56 These new compounds 
displayed better PAI-1 activity than tiplaxtinin and were able to inhibit the Michaelis-like 
complex that forms between PAI-1 and tPA/uPA. They were also importantly shown to inhibit 
victonectin-bound PAI-1. They were capable of reversibly binding to PAI-1 with high affinity, 
indicating their IC50 values were not time dependent. 
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Figure 4. Second generation synthesized compounds 
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Figure 4 (continued). Second generation synthesized compounds 
 
The structures of compounds CDE-004 (I-15) and CDE-066 (I-22) retained many of 
tannic acid’s gallate groups, and their anti-PAI-1 activity in the low nM range spurred further 
synthesis of molecules with fewer gallate groups to test the effect on activity against PAI-1. A 
concurrent goal was to investigate the linking unit’s role in the molecule’s activity. CDE-008 (I-
18), CDE-044 (I-16) and CDE-071 (I-17) were synthesized with these factors in mind. However, 
it was expected that the ester linkages would be susceptible to hydrolysis by esterases as well as 
by the acidic environment of the stomach. This made in vivo testing very limited and ruled out 
oral administration.56 In addition, it was found that this class of compounds did not typically 
retain activity against PAI-1 in ex vivo experiments containing plasma proteins, most likely due 
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to their ester linkages. On the other hand, those with more galloyl groups seemed to perform 
better against PAI-1 in plasma.  
 In an attempt to overcome this issue, the ester linkages were replaced with more stable 
bis-arylsulfonamides and aryl sulfonamide groups in a series of compounds (Table 1). It was 
found that molecules that contained two sulfonyl groups were most effective against PAI-1,63  
that 3,4-dihydroxy substitution gave the lowest IC50 values, and that some non-symmetric 
inhibitors also proved effective (CDE-187 and 198).63 While these molecules have shown 
promise and were further investigated by our research group, one of their major setbacks was 
loss of activity in assays containing plasma.30  
Table 1. Sulfonamide and sulfonimide based inhibitors 
CDE Code Structure IC50 Value (μM) 
CDE-032 
 
9.45 
CDE-119 
 
6134 
CDE-132 
 
1384 
CDE-135 
 
104 
CDE-140 
 
318 
16 
 
CDE-165 
 
0.35 
CDE-183 
 
0.18 
CDE-187 
 
0.91 
CDE-198 
 
0.051 
 
In order to find another lead compound, a second high throughput library screen was 
performed on a much larger set of molecules maintained by the Center for Chemical Genomics 
(CCG) at the University of Michigan. This screen discovered two main molecules with anti-PAI-
1 activity. Of these, I-24, was chosen for further studies due to its low molecular weight, low 
micromolar IC50 value of 36 μM, and suitability as a framework for synthesizing many 
derivatives. I-24 lacks any galloyl groups in exchange for a single benzene ring with a para 
17 
 
substituted chlorine, drawing electron density out of the ring. It also includes a highly active 
hydrazide on its opposite end. We decided that our research group would undertake the challenge 
of synthesizing a host of analogs to I-24 in order to better understand the structure activity 
relationships between various moieties in the compound and PAI-1 inhibition.  
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Variations Hydrazide 
Oxalyl Core 
Chapter II 
II-1: Novel Small Molecule Inhibitors of PAI-1 
 
 The main goal of my work was to improve the lead molecule’s IC50 value, as well as to 
analyze structure activity relationships of various structural features of this PAI-1 inhibitor. I 
pursued these goals by synthesizing various analogs of I-24 with variations at three locations: I 
substituted different groups on the aromatic ring, extended the oxalyl core chain length, and 
exchanged the hydrazide group on the end of the lead molecule with other moieties (Figure 5).   
 
 
Figure 5. Locations of analogue syntheses 
II-2: Aromatic Substituent Variations 
 My first objective was to vary substituents on the aromatic ring to study their effect on 
PAI-1 inhibitory activity. Scheme 1 details the general procedure for synthesizing these 
analogues. Substituted benzylamines were placed in a solution of pyridine and methylene 
chloride. To this, ethyl oxalyl chloride was added to form an ester intermediate. This ester was 
then dissolved in ethanol and treated with hydrazine hydrate to provide the final product to be 
analyzed for activity versus PAI-1.  
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Scheme 1. Synthesis of lead molecule analogs from benzene ring substitutions. Reagents 
and conditions: a. ethyl oxalyl chloride, pyridine, CH2Cl2, 0 ºC to r.t.; b. 
hydrazine hydrate, ethanol, r.t.  
 
 Following synthesis and verification of product via 1H NMR and 13C NMR, all products 
were tested in Dr. Lawrence’s lab for inhibitory activity versus PAI-1. Molecules were tested 
under two conditions: a simple pH 7.4 buffer with PAI-1 and uPA, and with the addition of 1.5% 
bovine serum albumin (BSA) to the pH 7.4 buffer. The BSA adds proteins that allow the assay to 
more closely mimic the physiological conditions of a whole organism. The molecules that were 
synthesized and their inhibitory assay results are shown in Table 2. 
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Table 2: Oxalyl core benzene ring substituent variations. 
Compound 
Code 
Category A 
R2 R3 R4 R5 R6 
IC50 
(μM) 
pH 7.4 
IC50 
(μM) 
1.5% 
BSA 
Lead (I-24) H H Cl H H 117 54 
CDE-486 H H OCHF2 H H >3000 324 
CDE-487 H H H H OCHF2 >3000 >3000 
CDE-488 F CF3 H H H 387 157 
CDE-492 F CH3 H H F 3188 1274 
CDE-493 F F F H H 809 267 
CDE-494 Cl F H H F >3000 >3000 
CDE-495 H CF3 F H H 247 99.6 
CDE-496 H H iPr H H 976 205 
CDE-497 H H N(CH3)2 H H >3000 469 
CDE-498 H H CH2CH3 H H 2679 134 
CDE-499 H CH3 F H H 268 90.7 
CDE-268a H OCF3 H H H 131 109 
aCompound synthesized by Naga Guntaka. Substituent locations shown in Scheme 1. 
 
Analysis of the data acquired for the analogues I synthesized suggests that an 
electronegative group in the para (R4) position on the ring leads to lower IC50 values. For 
example, when comparing CDE-486, with the substituent in the para position, and CDE-487, 
where it is meta, CDE-486 has a significantly lower IC50 in BSA.  
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A similar parallel is seen between CDE-492 and CDE-499. The inclusion of a fluorine 
atom in the para (R4) position of CDE-499 seems to have drastically improved its inhibition 
capability. It should be noted that the fluorine in the second position on the ring has been 
removed in CDE-499, which may have some effect in the change of IC50 values, as many 
compounds without an electron withdrawing group at that position show a trend of possessing 
lower IC50 values. 
                            
The data indicates a correlation between lower IC50 values and the presence of 
substituents in the para position, as well as a preference for electron withdrawing groups at that 
position, as opposed to electron donating groups. CDE-497 was synthesized with an electron 
donating tertiary nitrogen at the para position; while measurable inhibition does occur within the 
test range, it is noticeably worse than previous molecules that contain electron withdrawing 
groups at that position. In the same sense, CDE-496, containing an isopropyl group, which is far 
less withdrawing than the groups on some of the other molecules synthesized,  is also seen to 
have a more effective inhibitory effect than that of CDE-497.  
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It is interesting to note that there is a correlation between a substituent on the ortho (R6) 
position and a decreased inhibitory effect. CDE-493 and CDE-494 contain similar 
electronegative substituents, with the main difference being the position of the third substituent. 
CDE-493 contains a para (R4) substituent while CDE-494 has a second ortho (R6) substituent. 
This difference results in a significant decrease in inhibitory effect for CDE-494. This is also 
seen in the previous comparison of CDE-486 and CDE-487, as well as CDE-492, which has the 
third least effective IC50 value.  
                       
  
 
II-3: Extension of Core Chain Length Analogues 
 The second portion of my research was to determine the effect of extending the two -
carbon oxalyl core to the three and four carbon malonyl and succinyl cores, respectively (Figure 
6). In these cases only one benzyl amine was used for all syntheses. A trifluoromethoxy group on 
the meta (R3) position on the ring was utilized. This was done in an effort to keep the aromatic 
ring substitution consistent, as well as benefit from the previous use of this benzyl amine in the 
syntheses of similar molecules. In these syntheses, the hydrazide group was modified to match 
26 
 
 
other molecules with the original oxalyl core, where the molecules I synthesized and their 
inhibitory assay results are listed in Table 3 and Table 4; and their original counterparts are 
displayed in Table 5. 
 
Figure 6. Malonyl (a) and Succinyl (b) cores 
The intermediate esters leading to CDE compounds 501, 502, 503, 504, 505, 506, 509, 
511, 521, 522, 523, and 524 were synthesized in the same manner as previous benzyl amine 
analogues. 3-Trifluoromethoxy benzyl amine was added to a solution of methylene chloride and 
pyridine. Methyl malonyl chloride or methyl succinyl chloride was added dropwise to provide 
the resulting ester. The esters then underwent the appropriate reactions in order to afford the final 
compounds. CDE-502 and 511 were treated with hydrazine hydrate; CDE-503 and 521 were 
subjected to aqueous base; CDE-504, 505, 522, and 523 were reacted with a beta amide ester salt 
under standard peptide-coupling conditions; CDE-506 and 524 were treated with ammonia in 
methanol (7 N) (Scheme 2).                                                      
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Scheme 2. Syntheses of malonyl & succinyl compounds with varying end moieties. 
Reagent and conditions. (a): methyl malonyl chloride, pyridine, CH2Cl2, 0 ºC 
to rt. (b): methyl succinyl chloride, pyridine, CH2Cl2, 0 ºC to rt. (c):  CDE-502 
and CDE-511: hydrazine hydrate, EtOH; 503, 521: aq. NaOH (5M), EtOH; 
CDE-504, 522: 2-amino-1-pyrrolidin-1-yl-ethanone hydrochloride, HOBt · 
H2O, DMF, N-methylmorpholine, H2Cl2, EDC · HCl; CDE-505, 523: 2-
amino-1-morpholino-1-ethanone hydrochloride, HOBt · H2O, DMF, N-
methylmorpholine, H2Cl2, EDC · HCl; CDE-506 and CDE-524: ammonia in 
methanol, EtOH.  
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Table 3. Malonyl-based compounds. 
Compound Code X 
IC50 (μM) 
pH 7.4 
IC50 (μM) 
1.5% BSA 
CDE-509 OCH3 >3000 >3000 
CDE-511 NHNH2 >3000 >3000 
CDE-521 OH 721 >3000 
CDE-522 
 
>3000 >3000 
CDE-523 
 
>3000 >3000 
CDE-524 NH2 139 >3000 
 
 Table 4. Succinyl-based Compounds. 
Compound Code 
Category A 
X 
IC50 (μM) 
pH 7.4 
IC50 (μM) 
1.5% BSA 
CDE-501 OCH3 >3000 1383 
CDE-502 NHNH2 2017 801 
CDE-503 OH >3000 >3000 
CDE-504 
 
948 836 
CDE-505 
 
4273 2402 
CDE-506 NH2 921 3298 
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Table 5. Previously synthesized inhibitors. 
Compound Code X 
IC50 (μM) 
pH 7.4 
IC50 (μM) 
1.5% BSA 
CDE-471b NH2 421 156 
CDE-507a 
 
>3000 >3000 
CDE-489a 
 
>3000 2374 
Synthesized by: aJen Corker, bRaKeenja Fluellen.  
 
 The results seen in Table 6 give an interesting insight into the effect of core chain length 
on the results of the bio assays for this set of molecules. It was hypothesized that there would be 
a correlation between core length and activity, with one length consistently producing better 
results than the others. However, that is not the case here. The only consistent result is that 
molecules with the malonyl core have no activity when in a protein system. This could be due to 
the atypically acidic C-H bonds on the carbon chain being more susceptible to deprotonation 
and, therefore, the possible creation of unfavorable interactions with other proteins than those of 
the succinyl chain protons (the oxalyl chain contains no acidic protons between carbonyls). It is 
particularly intriguing that even the hydrazide extension on the malonyl core has no activity 
when every other assay has shown the hydrazide group to produce a significant increase in 
inhibitory effect.  
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Table 6. Direct comparison of varying core length inhibitors. 
 
X 
Oxalyl IC50 (μM) Malonyl IC50 (μM) Succinyl IC50 (μM) 
pH 7.4 1.5% 
BSA 
pH 7.4 1.5% 
BSA 
pH 7.4 1.5% 
BSA 
OCH3 - - >3000 >3000 >3000 1383 
NHNH2 131 109 >3000 >3000 2017 801 
OH - - 721 >3000 >3000 >3000 
 
>3000 >3000 >3000 >3000 948 836 
 
>3000 2374 >3000 >3000 4273 2402 
NH2 421 156 139 >3000 921 3298 
 
The oxalyl-based inhibitors exhibit better activity than either of the malonyl or succinyl 
compounds; however, the compound containing the morpholine ring has nearly the same IC50 as 
the succinyl compound, offsetting the trend. Future research could explore further extension of 
the core in order to assess the inhibitory effect of chain length, as well as other various end 
moieties. 
 
II-4: Alpha-Beta Unsaturated Malonyl Derivatives 
 In an effort to increase our understanding of the relationship of structure to inhibition 
activity, our group is synthesizing an increasingly diverse set of molecules. One of the benefits 
of extending the core length from our lead molecule to a malonyl core is the ability to utilize the 
alpha-carbon at each carbonyl as a reactive center for new reactions. I focused on employing a 
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Knoevenagel reaction, which converts the sp3-hybridized carbon at the carbonyl position to an 
sp2-hybridized carbon bound to an additional group. In a microwave tube, I added an aldehyde of 
choice and piperidine to the previously synthesized malonyl ester (CDE-509). Later syntheses 
involved the addition of ethyl alcohol as a solvent. The mixture was then subjected to microwave 
irradiation at 100 ºC for 7.5 minutes, followed by an acidic workup (Scheme 3). 
          
 Scheme 3. Synthesis of alpha-beta unsaturated malonyl derivatives. Reagents & 
conditions: Piperidine (0.25 eq.), various aldehyde (5 eq.). Microwave irradiation at 250W, 100 
ºC, 7.5 minutes, no stirring. Later syntheses involved the addition of EtOH as solvent. 
 
The first attempt was made using butyraldehyde (Scheme 4). Preliminary TLC results 
suggested contamination by side reactions so the product was purified by column 
chromatography. Post column TLC staining revealed persistent contamination. Preliminary 1H-
NMR indicated a lack of product as well as too many side products to warrant further pursuit. 
This first attempt was therefore abandoned and a second aldehyde was tried. 
 
 
 Scheme 4. Synthesis of alpha-beta unsaturated malonyl derivative using butyraldehyde. 
Reagents & conditions: Piperidine (0.25 eq.), butyraldehyde (5 eq.) Microwave irradiation at 
250W, 100ºC, 7.5 minutes, no stirring. 
 
Nonanal was used in an attempt to drive the reaction forward in a more stereo-selective 
manner due to its long aliphatic chain while keeping the chemistry similar (Scheme 5). In the 
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same way, the aldehyde was added to a microwave tube with piperidine and the starting malonyl 
ester, then placed in the microwave at 100 ºC for 7.5 minutes. Following an acid workup, a 
column was run in 1% ethyl acetate:hexanes. 1H-NMR analysis of the resulting separated 
compounds was inconclusive, and therefore, further TLC staining was performed. Again, this 
revealed multiple, previously unseen “spots”, and therefore, any further attempts at purification 
were dismissed. 
 
Scheme 5. Synthesis of alpha-beta unsaturated malonyl derivative using nonanal. 
Reagents & conditions: Piperidine (0.25 eq.), nonanal (5 eq.) Microwave irradiation at 250W, 
100 ºC, 7.5 minutes, no stirring. 
 
  A third attempt at making the desired Knoevenagel reaction proceed correctly 
was via the use of veratraldehyde (Scheme 6). This aldehyde was chosen due to its bulky 
aromatic group, with hopes that its steric bulk would help drive the reaction towards selectively 
producing a single isomer. CDE-512 was obtained after workup and a column run in 40% ethyl 
acetate:hexanes. 2D NMR techniques were then utilized to verify that the Z isomer of CDE-512 
was the nearly exclusive product (I-25).  
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Scheme 6. Synthesis of alpha-beta unsaturated malonyl derivative using veratraldehyde. 
Reagents & conditions: Piperidine (0.25 eq.), veratraldehyde (5 eq.) Microwave irradiation at 
250W, 100 ºC, 7.5 minutes, no stirring. 
 
 
1D 1H-NMR, 1D 13C-NMR, COSY, HMQC, and NOESY were used to determine the 
stereochemistry of CDE-512. Evidence of the exclusive formation of the Z isomer was provided 
mostly by the interactions in the NOESY spectrum of the amide hydrogen solely with its 
neighboring benzylic hydrogens (Figure 7). No other spatial interactions were observed, had the 
E isomer been present, it would likely have shown an interaction between the amide hydrogen 
and the second aromatic ring.  
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Figure 7. NOESY data of CDE-512. Red box indicates interaction between amide 
hydrogen & benzylic protons. Lack of any other interactions gives evidence of Z isomer. 
 
It may be argued that if CDE-512 were in the Z conformation we would see interactions 
between the vinylic hydrogen and the hydrogen on the amine, which was not observed. This may 
be due to a lack of specificity in the experiment or these hydrogens being too far away to have 
any interactions while in the Z conformation. Molecular modeling suggests that the amide 
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hydrogen could be pointed away from the vinylic proton which also may explain the lack of 
interaction between the two. 
We suspected that CDE-512 would show little activity versus PAI-1 due to its lack of a 
hydrazide group. However, we were surprised by an almost complete lack of any activity, even 
in very concentrated amounts (3000 µM). Formation of the hydrazide analog was then attempted 
using previously-detailed methods (Scheme 7). Hydrazine hydrate was added to a solution of 
CDE-512 in ethanol. Through multiple TLC and column runs, it was determined that no desired 
hydrazide product was formed and we decided to undertake another method.  
 
Scheme 7. Formation of hydrazide from alpha-beta unsaturated malonyl compound. 
Reagents & conditions: CDE-512 (1 eq.), hydrazine hydrate (2 eq.), ethanol, 24 hours, r.t. 
 
I attempted to synthesize the desired product by subjecting the previously synthesized 
malonyl hydrazide (CDE-511) in place of the ester (CDE-509) to the Knoevenagel reaction 
(Scheme 8). In a microwave tube, the malonyl hydrazide was combined with 0.25 eq of 
piperidine, 5 eq of veratraldehyde and 1 mL of EtOH and the reaction mixture was subjected to 
the same conditions as before. A number of different species were identified via TLC and a 
column was run to isolate the unidentified products. The 1H NMR spectrum was inconclusive as 
to the identity of the products, and therefore, we performed a second synthesis in an effort to 
obtain the desired products.  
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Scheme 8. Alternate synthesis for the formation of hydrazide malonyl compound 
using veratraldehyde. Reagents & conditions: CDE-511 (1 eq.), Piperidine (0.25 eq.), 
veratraldehyde (5 eq.), ethanol (2 mL). Microwave irradiation at 250W, 100 ºC, 7.5 minutes, 
stirring. 
 
In the same manner as before, I added the malonyl hydrazide to a microwave tube with 
piperidine, EtOH and butyraldehyde (Scheme 9). I used butyraldehyde again despite the 
previous lack of success because it is a much easier molecule to identify via NMR. In particular, 
I was looking for the absence of carbonyl alpha protons as well as the presence of a single 
vinylic proton, which could be easily masked by veratraldehyde in an impure sample. The 
resulting product was triturated with diethyl ether and a white granular solid was obtained. After 
drying under vacuum, the sample was subjected to 1H-NMR. We found a near 1:1 ratio of E : Z 
isomers; however carbonyl alpha protons were still present near 3.1 ppm and 3.4 ppm. This led 
me to the conclusion that I had formed the hydrazone instead (Figure 8).  
 
Scheme 9. Alternate synthesis for the formation of hydrazide malonyl compound 
using butyraldehyde. Reagents & conditions: CDE-511 (1 eq.), Piperidine (0.25 eq.), 
butyraldehyde (5 eq.), ethanol (2 mL). Microwave irradiation at 250W, 100 ºC, 7.5 minutes, 
stirring. 
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Figure 8. Hydrazone butyraldehyde product reaction 
 The same analysis was applied to the previously observed veratraldehyde/hydrazide 1H-
NMR. Two singlet peaks from protons alpha to the carbonylsin isomers of the undesirable 
hydrazone product were identified (Figure 9). As a consequence of these results and due to 
additional impurities, the synthesis of this compound was not pursued further. 
 
Figure 9. Hydrazone product of veratraldehyde 
However, the butyraldehyde hydrazone isomers were of higher purity, and we could 
perform further attempts to obtain the desired hydrazide product. I attempted to add the 
veratraldehyde to the originally intended position, hoping that I could reverse the formation of 
the hydrazone back to the hydrazide following the successful addition of veratraldehyde to the 
compound (Scheme 10). I exposed the hydrazone with the common reagents and veratraldehyde 
to microwave irradiation as detailed above.  
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 Scheme 10. Synthesis of hydrazone with veratraldehyde. Reagents & conditions: 
Piperidine (0.25 eq.), veratraldehyde (5 eq.), ethanol (3 mL). Microwave irradiation at 250W, 
100 ºC, 7.5 minutes, stirring. 
 
Following an acidic workup, TLC was analyzed and it was found that no reaction had 
taken place. At this point I had a near homogenous solid of starting hydrazone and 
veratraldehyde, and therefore, decided to try one last reaction with what little materials I had left.  
The recovered starting materials from Scheme 10 were dissolved in EtOH and 4 drops of 
glacial acetic acid were added. The sample underwent microwave irradiation for 35 minutes, 
followed by an acid workup as well as a trituration following preliminary NMR. This reaction 
did not proceed and only miniscule amounts of starting material remained. In the future it could 
be beneficial to revisit this reaction path. We have observed that the acidic protons in the carbon 
chain of the other malonyl-based compounds are likely the cause of instability in protein assays. 
Minor alterations at this site could lead to more potent inhibitors as both the terminal alcohol and 
amine compounds had moderate inhibition in pH 7.4 buffer. If those compounds could be 
stabilized, it would be advantageous to test their inhibitory effects in a protein assay. 
 
II-5: Conclusions 
 The objective of my research was to synthesize novel small molecules as inhibitors of 
plasminogen activator inhibitor-1. I synthesized a series of compounds that can be added to a 
small library of analogues based around the lead molecule, I-24. I varied three aspects of the 
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structure of these compounds. First I altered the nature and position of substituents to the 
benzene ring while keeping the rest of the molecule the same. I found that there is a positive 
correlation between inhibitory effect and the presence of an electronegative group at the para 
(R4) position. In addition, a substituent at the ortho (R2 or R6) position tends to weaken the 
inhibitory effect.  The second structural modification was to extend the carbon core of the lead 
molecule and the third modification was to remove and substitute the hydrazine end. Results 
from these two modifications varied, but it is clear that the three carbon chain malonyl molecules 
are significantly less effective than the two carbon oxalyl or four carbon succinyl molecules.  
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Experimental Methods & Data 
 
Ethyl 2-((4-(difluoromethoxy)benzyl)amino)-2-oxoacetate (KMU-1-1): To a solution of 4-
(difluoromethoxy)benzylamine (0.265 mL, 1.83 mmol) and pyridine (0.30 mL, 3.66 mmol) in 
2.0 mL of CH2Cl2 stirred in an ice bath, ethylchlorooxoacetate (0.21 mL, 1.92 mmol) was added 
dropwise. The reaction was allowed to stir for one hour. The reaction mixture was then diluted 
with 30 mL ethyl acetate and washed with 2 × 25 mL of 0.2N HCl, followed by 2 × 25 mL sat. 
aqueous NaHCO3. The organic phase was then dried with anhydrous MgSO4, filtered and 
concentrated to provide 335.0 mg (67.1%) of the pale yellow solid. 1H-NMR (CDCl3, 400 MHz) 
δ 7.52 (bs, 1H), 7.52 (bs, 1H), 7.27 (d, J=8.7 Hz, 2H), 7.05 (d, J=8.7 Hz, 2H), 6.47 (t, J=6.4 Hz, 
2H), 4.29 (q, J=7.32 Hz, 2H), 1.34 (t, J=6.88 Hz, 3H). 
 
 
N-(4-(difluoromethoxy)benzyl)-2-hydrazinyl-2-oxoacetamide (CDE-486):  A solution of 
KMU-1-1 (157.1 mg, 0.549 mmol) and hydrazine hydrate (0.068 mL, 1.098 mmol, ~50% in 
H2O) in 4 mL ethanol was stirred for one hour at room temperature. The amorphous solid was 
filtered and dried under high vacuum to provide 305.0 mg (quantitative yield) of CDE-486 as an 
off-white solid. 1H NMR (DMSO-d6, 400 MHz) δ 10.00 (bs, 1H), 9.25 (t, J=5.9 Hz, 1H), 7.17 
(dd, J=8.7 Hz, 75.6 Hz, 4H), 7.15 (t, J=74.7 Hz, 1H), 4.50 (bs, 2H), 4.25 (d, J=6.44 Hz, 2H). 
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13C NMR (DMSO-d6, 100 MHz) δ 160.35, 158.55, 150.36, 136.44, 129.57, 119.26, 116.92 (t, 
J=256.5 Hz), 40.23; HRMS, DART calcd. for C10H11F2N3O3 [M+H+] 260.08467, found: 
260.08401. 
 
Ethyl 2-((2-(difluoromethoxy)benzyl)amino)-2-oxoacetate (KMU-1-3): The procedure for the 
synthesis of KMU-1-1 was followed, substituting 4-(difluoromethoxy)benzylamine for 2-
(difluoromethoxy)benzylamine which gave 471.2 mg (94.4%) of KMU-1-3 as a yellow solid. 1H 
NMR (CDCl3, 400 MHz) δ 7.80 (m, 5H), 6.58 (t, J=73.7 Hz, 1H), 4.56 (d, J=5.96 Hz, 2H), 4.33 
(q, J=7.32 Hz, 2H), 1.37 (t, J=7.32 Hz, 3H).  
 
N-(2-(difluoromethoxy)benzyl)-2-hydrazinyl-2-oxoacetamide (CDE-487): A solution of 
KMU-1-3 (124.7 mg, 0.456 mmol) and hydrazine hydrate (0.058 mL, 0.912 mmol, ~50% in 
H2O) in 4 mL ethanol was stirred for one hour at room temperature. The amorphous solid was 
filtered and dried under high vacuum to provide 68.5 mg (58.1%) of CDE-487 as a white solid. 
1H NMR (DMSO-d6, 400 MHz) δ 10.04 (bs, 1H), 9.13 (t, J=6 Hz, 1H), 7.20 (m, 5H), 4.51 (bs, 
2H), 4.32 (d, J=6 Hz, 2H). 13C NMR (DMSO-d6, 100 MHz) δ 160.54, 158.41, 148.98, 129.96, 
129.08, 128.95, 125.81, 118.86, 117.13 (t, J=257.4 Hz), 37.41; HRMS, DART calcd. for 
C10H11F2N3O3 [M+H+] 260.08467, found: 260.08301. 
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Ethyl 2-((2-fluoro-3-(trifluoromethyl)benzyl)amino)-2-oxoacetate (KMU-1-4): The 
procedure for the synthesis of KMU-1-1 was followed, substituting 4-(difluoromethoxy)-
benzylamine for 2-fluoro-3-(trifluoromethyl)benzylamine which gave 487.9 mg (91.0%) of 
KMU-1-4 as a white solid. 1H NMR (CDCl3, 400 MHz) δ 7.57 (m, 3H), 7.21 (t, J=7.8 Hz, 1H), 
4.6 (d, J=6.4 Hz, 2H), 4.34 (q, J=7.4 Hz, 2H), 1.37 (t, J=7.3 Hz, 3H).  
 
N-(2-fluoro-3-(trifluoromethyl)benzyl)-2-hydrazinyl-2-oxoacetamide (CDE-488): A solution 
of KMU-1-4 (116.4 mg, 0.397 mmol) and hydrazine hydrate (0.049 mL, 0.794 mmol, ~50% in 
H2O) in 4 mL ethanol was stirred for one hour at room temperature. The amorphous solid was 
filtered and dried under high vacuum to provide 50.3 mg (45.7%) of CDE-488 as a white solid. 
1H NMR (DMSO-d6, 400 MHz) δ 10.06 (bs, 1H), 9.33 (t, J=6.4 Hz, 1H), 7.61 (dt, J=6.9 Hz, 
J=22.9 Hz, 2H), 7.34 (t, J=7.8 Hz, 1H), 4.51 (d, J=4.1 Hz, 2H), 4.39 (d, J=6 Hz, 2H). 13C NMR 
(DMSO-d6, 100 MHz) δ 160.63, 158.25, 157.20 (d, J=254.6 Hz), 134.97 (d, J=4.8 Hz), 127.9 (d, 
J=13.4 Hz), 126.48 (d, J=4.8 Hz), 125.26 (d, J=3.8 Hz), 123.25 (q, J=269.8 Hz), 116.9 (m), 
36.19 (d, J=4.8 Hz); HRMS, DART calcd. for C10H9F4N3O2 [M+H+] 280.07090, found: 
280.07199. 
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Ethyl 2-((2,6-difluoro-3-methylbenzyl)amino)-2-oxoacetate (KMU-1-7): The procedure for 
the synthesis of KMU-1-1 was followed, substituting 4-(difluoromethoxy)-benzylamine for 2,6-
difluoro-3-methylbenzylamine which gave 435.8 mg (92.7%) of KMU-1-7 as an off-white solid. 
1H NMR (CDCl3, 400 MHz) δ 7.31 (bs, 1H), 7.1 (q, J=8.7 Hz, 1H), 6.8 (t, J=8.7 Hz, 1H), 4.6 (d, 
J=6 Hz, 2H), 4.32 (q, J=7.3 Hz, 2H), 2.23 (t, J=0.9 Hz, 3H), 1.37 (t, J=6.9 Hz, 3H).  
 
N-(2,6-difluoro-3-methylbenzyl)-2-hydrazinyl-2-oxoacetamide (CDE-492): A solution of 
KMU-1-7 (152.2 mg, 0.592 mmol) and hydrazine hydrate (0.074 mL, 1.184 mmol, ~50% in 
H2O) in 6 mL ethanol was stirred for one hour at room temperature. The solid was filtered and 
dried under high vacuum to provide 118.5 mg (82.3%) of CDE-492 as a white solid. 1H NMR 
(DMSO-d6, 400 MHz) δ 9.99 (bs, 1H), 8.97 (t, J=6 Hz, 1H), 7.2 (q, J=8.2 Hz, 1H), 6.92 (t, J=9 
Hz, 1H), 4.47 (bs, 2H), 4.34 (d, J=5.5 Hz, 2H), 2.14 (s, 3H). 13C NMR (DMSO-d6, 100 MHz) δ 
160.04, 159.66 (dd, J=8.58 Hz, J=244.1 Hz), 159.57 (dd, J=8.59 Hz, J= 246.0 Hz), 158.39, 
131.14 (dd, J=6.7 Hz, J=9.5 Hz), 120.60 (dd, J=3.81 Hz, J=18.11 Hz), 113.58 (t, J=19.1 Hz), 
111.20 (dd, J=3.8 Hz, J=21.9 Hz), 31.57, 14.25 (d, J=2.9 Hz); HRMS, DART calcd. for 
C10H11F2N3O2 [M+H+] 244.08976, found: 244.08900. 
 
 
Ethyl 2-oxo-2-((2,3,4-trifluorobenzyl)amino)acetate (KMU-1-12): The procedure for the 
synthesis of KMU-1-1 was followed, substituting 4-(difluoromethoxy)-benzylamine for 2,3,4-
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trifluorobenzylamine which gave 420.6 mg (88.1%) of KMU-1-12 as an off-white solid. 1H 
NMR (CDCl3, 400 MHz) δ 7.43 (bs, 1H), 7.10 (m, 1H), 6.93 (ddt, J=6.9 Hz, J=6.9 Hz, J=6.9 
Hz, 1H), 4.54 (d, J=6.4 Hz, 2H), 4.34 (q, J=6.8 Hz, 2H), 1.38 (t, J=6.9 Hz, 3H).  
 
2-hydrazinyl-2-oxo-N-(2,3,4-trifluorobenzyl)acetamide (CDE-493): A solution of KMU-1-12 
(139.9 mg, 0.538 mmol) and hydrazine hydrate (0.067 mL, 1.071 mmol, ~50% in H2O) in 6 mL 
ethanol was stirred for one hour at room temperature with manual breakup of the solid required. 
The sturdy solid was filtered and dried under high vacuum to provide 104.2 mg (78.8%) of 
CDE-493 as an off-white stiff solid. 1H NMR (DMSO-d6, 400 MHz) δ 10.04 (bs, 1H), 9.28 (t, 
J=6 Hz, 1H), 7.24 (m, 1H), 7.11 (m, 1H), 4.51 (bs, 2H), 4.32 (d, J=6 Hz, 2H). 13C NMR 
(DMSO-d6, 100 MHz) δ 160.53, 158.25, 149.90 (ddd, J=2.8 Hz, J=9.5 Hz, J=245.0 Hz), 148.96 
(ddd, J=2.8 Hz, J=10.5 Hz, J=247.0 Hz), 139.33 (dt, J= 15.3 Hz, J=246.9 Hz), 124.37 (m), 
124.10 (dd, J=2.8 Hz, J=12.4 Hz), 112.90 (dd, J=2.8 Hz, J=16.2 Hz), 36.06; HRMS, DART 
calcd. for C9H8F3N3O2 [M+H+] 248.06468, found: 248.06300. 
 
 
Ethyl 2-((2-chloro-3,6-difluorobenzyl)amino)-2-oxoacetate (KMU-1-8): The procedure for 
the synthesis of KMU-1-1 was followed, substituting 4-(difluoromethoxy)-benzylamine for 2-
chloro-3,6-difluorobenzylamine which gave 401.2 mg (79.1%) of KMU-1-8 as an off-white 
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solid. 1H NMR (CDCl3, 400 MHz) δ 7.35 (bs, 1H), 7.12 (m, 1H), 7.01 (m, 1H), 4.71 (dd, J=1.4 
Hz, J=6.0 Hz, 2H), 4.33 (q, J=7.4 Hz, 2H), 1.37 (t, J=6.9 Hz, 3H). 
 
N-(2-chloro-3,6-difluorobenzyl)-2-hydrazinyl-2-oxoacetamide (CDE-494): A solution of 
KMU-1-8 (148.8 mg, 0.536 mmol) and hydrazine hydrate (0.067 mL, 1.072 mmol, ~50% in 
H2O) in 4 mL ethanol was stirred for one hour at room temperature. The solid was filtered and 
dried under high vacuum to provide 87.2 mg (61.8%) of CDE-494 as a white, granular solid. 1H 
NMR (DMSO-d6, 400 MHz) δ 10.01 (bs, 1H), 9.03 (bs, 1H), 7.39 (m, 1H), 7.24 (m, 1H) 
4.49 (bs, 2H), 4.42 (d, J=5.5 Hz, 2H). 13C NMR (DMSO-d6, 100 MHz) δ 160.19, 158.26, 157.64 
(d, J=244.1 Hz), 154.45 (d, J=240.1 Hz), 125.52 (d, J=19.1 Hz), 121.91 (dd, J=19.1 Hz, J=5.7 
Hz), 116.90 (dd, J=23.8 Hz, J=9.5 Hz), 115.62 (dd, J=25.7 Hz, J=8.6 Hz), 35.16; HRMS, 
DART calcd. for C9H8ClF2N3O2 [M+H+] 264.03514, found: 264.03601. 
 
 
 
Ethyl 2-((4-fluoro-3-(trifluoromethyl)benzyl)amino)-2-oxoacetate (KMU-1-11): The 
procedure for the synthesis of KMU-1-1 was followed, substituting 4-(difluoromethoxy)-
benzylamine for 4-fluoro-3-(trifluoromethyl)benzylamine which gave 462.5 mg (86.2%) of 
KMU-1-11 as a yellow solid. 1H NMR (CDCl3, 400 MHz) δ 7.51 (m, 3H), 7.18 (t, J=9.6 Hz, 
1H), 4.53 (d, J=6.4 Hz, 2H), 4.36 (q, J=7.3 Hz, 2H), 1.39 (t, J=6.9 Hz, 3H). 
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N-(4-fluoro-3-(trifluoromethyl)benzyl)-2-hydrazinyl-2-oxoacetamide (CDE-495): A solution 
of KMU-1-11 (140.8 mg, 0.480 mmol) and hydrazine hydrate (0.060 mL, 0.961 mmol, ~50% in 
H2O) in 5.1 mL ethanol was stirred for one hour at room temperature. The solid was filtered and 
dried under high vacuum to provide 90.6 mg (67.6%) of CDE-495 as a white solid. 1H NMR 
(DMSO-d6, 400 MHz) δ 10.04 (bs, 1H), 9.36 (t, J=6 Hz, 1H), 7.64 (d, J=6.9 Hz, 1H), 7.59 (m, 
1H), 7.42 (t, J=10.5 Hz, 1H), 4.50 (bs, 2H), 4.32 (d, J=6 Hz, 2H). 13C NMR (DMSO-d6, 100 
MHz) δ 160.53, 158.35, 158.32 (d, J=252.7 Hz), 136.54 (d, J=2.9 Hz), 134.81 (d, J=8.6 Hz), 
126.69 (d, J=3.8 Hz), 122.52 (q, J=269.8 Hz), 117.61 (d, J=21.0 Hz), 116.70 (dd, J=31.5 Hz, 
J=12.4 Hz), 41.72; HRMS, DART calcd. for C10H9F4N3O2 [M+H+] 280.07090, found: 
280.06799. 
 
 
Ethyl 2-((4-isopropylbenzyl)amino)-2-oxoacetate (KMU-1-17): The procedure for the 
synthesis of KMU-1-1 was followed, substituting 4-(difluoromethoxy)-benzylamine for 4-
isopropylbenzylamine which gave 367.0 mg (80.7%) of KMU-1-17 as a pale white solid. 1H 
NMR (CDCl3, 400 MHz) δ 7.32 (bs, 1H), 7.22 (m, 4H), 4.47 (d, J=6 Hz, 2H), 4.34 (q, J=7.3 Hz, 
2H), 2.9 (sep, J=6.9 Hz, 1H), 1.38 (t, J=7.3 Hz, 3H), 1.23 (d, J=6.9 Hz, 6H). 
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2-hydrazinyl-N-(4-isopropylbenzyl)-2-oxoacetamide (CDE-496): A solution of KMU-1-17 
(160.1 mg, 0.642 mmol) and hydrazine hydrate (0.080 mL, 1.284 mmol, ~50% in H2O) in 6 mL 
ethanol was stirred for one hour at room temperature with manual breakup of the solid required. 
The solid was filtered and dried under high vacuum to provide 118.4 mg (78.7%) of CDE-496 as 
a hard white solid. 1H NMR (DMSO-d6, 400 MHz) δ 10.00 (bs, 1H), 9.17 (t, J=6.4 Hz, 1H), 7.14 
(s, 4H), 4.50 (bs, 2H), 4.24 (d, J=6.4 Hz, 2H), 2.81 (sep, J=7.3 Hz, 1H), 1.13 (d, J=6.9 Hz, 6H). 
13C NMR (DMSO-d6, 100 MHz) δ 160.26, 158.64, 147.58, 136.77, 127.94, 126.68, 42.44, 33.65, 
24.46; HRMS, DART calcd. for C12H17N3O2 [M+H+] 236.13991, found: 236.13901.  
 
 
Ethyl 2-((4-(dimethylamino)benzyl)amino)-2-oxoacetate (KMU-1-19): To a solution of 4-
(dimethylamino)benzylamine (0.270 mL, 1.83 mmol) and triethylamine (0.509 mL, 3.66 mmol) 
in 2.05 mL of CH2Cl2 stirred in an ice bath, ethylchlorooxoacetate (0.21 mL, 1.92 mmol) was 
added dropwise. The reaction was allowed to stir for one hour. The reaction mixture was then 
diluted with 30 mL ethyl acetate and washed with 2 × 25 mL of 0.2N HCl, followed by 2 × 25 
mL sat. aqueous NaHCO3. The organic phase was then dried with anhydrous MgSO4, filtered 
and concentrated to provide 766.0 mg (quantitative yield) of KMU-1-19 as an impure solid.  1H 
48 
 
NMR (CDCl3, 400 MHz) δ 7.29 (m, 1H), 6.66 (m, 4H), 4.4 (d, J=5.5 Hz, 2H), 4.24 (q, J=7.3 
Hz, 2H), 2.94 (s, 6H), 1.36 (m, 3H). 
 
N-(4-(dimethylamino)benzyl)-2-hydrazinyl-2-oxoacetamide (CDE-497): A solution of KMU-
1-19 (199.2 mg, 0.796 mmol) and hydrazine hydrate (0.099 mL, 1.592 mmol, ~50% in H2O) in 4 
mL ethanol was stirred for one hour at room temperature. The solid was filtered and dried under 
high vacuum to provide 37.5 mg (20.0%) of CDE-497 as a white solid. 1H NMR (DMSO-d6, 400 
MHz) δ 9.97 (bs, 1H), 9.02 (t, J=6 Hz, 1H), 7.05 (d, J=8.3 Hz, 2H), 6.62 (d, J=8.7 Hz, 2H), 4.46 
(bs, 2H), 4.15 (d, J=6.4 Hz, 2H), 2.81 (s, 6H). 13C NMR (DMSO-d6, 100 MHz) δ 160.01, 
158.74, 150.16, 128.98, 126.89, 112.80, 42.23, 40.79; HRMS, DART calcd. for C11H16N4O2 
[M+H+] 237.13514, found: 237.13499. 
 
Ethyl 2-((4-ethylbenzyl)amino)-2-oxoacetate (KMU-1-22): The procedure for the synthesis of 
KMU-1-1 was followed, substituting 4-(difluoromethoxy)-benzylamine for 4- ethylbenzylamine 
which gave 341.0 mg (79.4%) of KMU-1-22 as a yellow oil.  1H NMR (CDCl3, 400 MHz) δ 
7.32 (bs, 1H), 7.19 (q, J=8.2 Hz, 4H), 4.47 (d, J=6 Hz, 2H), 4.34 (q, J=6.9 Hz, 2H), 2.63 (q, 
J=7.8 Hz, 2H), 1.38 (t, J=6.9 Hz, 3H), 1.22 (t, J=7.3 Hz, 3H).  
49 
 
 
N-(4-ethylbenzyl)-2-hydrazinyl-2-oxoacetamide (CDE-498): A solution of KMU-1-22 (138.5 
mg, 0.589 mmol) and hydrazine hydrate (0.073 mL, 1.178 mmol, ~50% in H2O) in 4 mL ethanol 
was stirred for one hour at room temperature. The solid was filtered and dried under high 
vacuum to provide 100.8 mg (76.9%) of CDE-498 as an off-white solid. 1H NMR (DMSO-d6, 
400 MHz) δ 9.99 (s, 1H), 9.16 (t, J=6.4 Hz, 1H), 7.12 (q, J=5 Hz, 4H), 4.49 (bs, 2H), 4.24 (d, 
J=6.4 Hz, 2H), 2.52 (q, J=7.3 Hz, 2H), 1.12 (t, J=7.3 Hz, 3H). 13C NMR (DMSO-d6, 100 MHz) 
δ 160.26, 158.64, 142.92, 136.62, 128.17, 127.94, 42.44, 28.34, 16.27; HRMS, DART calcd. for 
C11H15N3O2 [M+H+] 222.12425, found: 222.12199. 
 
Ethyl 2-((4-fluoro-3-methylbenzyl)amino)-2-oxoacetate (KMU-1-23): The procedure for the 
synthesis of KMU-1-1 was followed, substituting 4-(difluoromethoxy)-benzylamine for 4-
fluoro-3-methylbenzylamine which gave 341.0 mg (79.4%) of KMU-1-22 as a yellow oil.  1H 
NMR (CDCl3, 400 MHz) δ 7.34 (bs, 1H), 7.08 (m, 2H), 6.96 (t, J=9.2 Hz, 1H), 4.43 (d, J=6 Hz, 
2H), 4.34 (q, J=7.4 Hz, 2H), 2.25 (d, J=1.8 Hz, 3H), 1.38 (t, J=7.3 Hz, 3H).  
 
N-(4-fluoro-3-methylbenzyl)-2-hydrazinyl-2-oxoacetamide (CDE-499): A solution of KMU-
1-23 (186.9 mg, 0.782 mmol) and hydrazine hydrate (0.097 mL, 1.563 mmol, ~50% in H2O) in 4 
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mL ethanol was stirred for one hour at room temperature. The solid was filtered and dried under 
high vacuum to provide 149.6 mg (85.5%) of CDE-499 as a white solid. 1H NMR (DMSO-d6, 
400 MHz) δ 10.00 (s, 1H), 9.2 (t, J=6 Hz, 1H), 7.05 (m, 3H), 4.49 (bs, 2H), 4.22 (d, J=6.4 Hz, 
2H), 2.16 (s, 3H). 13C NMR (DMSO-d6, 100 MHz) δ 160.29, 160.20 (d, J=240.3 Hz), 158.57, 
135.22 (d, J=3.8 Hz), 131.13 (d, J=5.7 Hz), 127.18 (d, J=7.6 Hz), 124.30 (d, J=17.2 Hz), 
115.17 (d, J=22.9 Hz), 42.01, 14.67 (d, J=2.9 Hz); HRMS, DART calcd. for C10H12FN3O2 
[M+H+] 226.09918, found: 226.09900. 
 
Methyl 4-oxo-4-((3-(trifluoromethoxy)benzyl)amino)butanoate (CDE-501): To a solution of 
3-(trifluoromethoxy)benzylamine (1.03 mL, 3.66 mmol) and pyridine (1.16 mL, 3.84 mmol) in 
CH2Cl2 (20 mL) stirred in an ice bath, methyl-4-chloro-4-oxobutyrate (1.16 mL, 7.32 mmol) was 
added dropwise. The reaction was allowed to react overnight, warming to room temperature. The 
solution was then diluted with ethyl acetate and washed with 2 × 25 mL 0.2N HCl and 2 × 25 
mL NaHCO3. The organic phase was dried with anhydrous MgSO4, filtered and dried under 
vacuum to yield 1.7634 g (80.1%) of a viscous off-white material. 1H NMR (CDCl3, 400 MHz) δ 
7.34 (t, J=8.7 Hz, 1H), 7.19 (d, J=7.4 Hz, 1H), 7.11 (bs, 2H), 6.10 (bs, 1H), 4.45 (d, J=6 Hz, 2H), 
3.68 (m, 3H), 2.61 (tt, J=6.9 Hz, J=73.8 Hz, 4H). 13C NMR (CDCl3, 100 MHz) δ 173.57, 171.63, 
149.53, 140.86, 130.07, 125.95, 120.50 (q, J=255.5 Hz), 120.09, 119.83, 51.92, 43.00, 30.99, 
19.33; HRMS, DART calcd. for C13H14F3NO4 [M+H+] 306.09532, found: 306.09799. 
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4-hydrazinyl-4-oxo-N-(3-(trifluoromethoxy)benzyl)butanamide (CDE-502): A solution of 
CDE-501 (121.0 mg, 0.397 mmol) and hydrazine hydrate (0.247 mL, 3.970 mmol, ~50% in 
H2O) in ethanol 3.90 mL was allowed to stir overnight. 2 drops of RO H2O was added and 
product formation was verified via TLC (30:70 EtOAC:Hexanes). The solution was rotovapped 
and dried under vacuum, giving yield to 92.4 mg (73.4%) of a white solid, CDE-502. 1H NMR 
(DMSO-d6, 400 MHz) δ 8.93 (bs, 1H), 8.41 (t, J=5.5 Hz, 1H), 7.41 (m, 1H), 7.20 (m, 3H), 4.26 
(d, J=6 Hz, 2H), 4.09 (bs, 2H), 2.37 (m, 2H), 2.24 (m, 2H). 13C NMR (DMSO-d6, 100 MHz) δ 
172.00, 171.37, 148.96, 143.19, 130.41, 126.67, 120.77 (q, J=254.6 Hz), 119.99, 119.64, 41.97, 
31.16, 29.37; HRMS, DART calcd. for C12H14F3N3O3 [M+H+] 306.10655, found: 306.10001. 
 
 
 
4-oxo-4-((3-(trifluoromethoxy)benzyl)amino)butanoic acid (CDE-503): A solution of CDE-
501 (494.1 mg, 1.62 mmol) in 4 mL EtOH, 5 M NaOH (1.296 mL, 6.48 mmol) was added and 
allowed to stir overnight. The reaction solution was diluted with 30 mL EtOAc, and washed with 
2 × 25 mL 0.2 N HCl and 2 × 25 mL brine. The organic layer was dried with MgSO4, filtered 
and the solvent was evaporated to yield 386.5 mg (82.0%) of CDE-503 as a brittle white solid. 
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1H NMR (DMSO-d6, 400 MHz) δ 12.05 (bs, 1h), 8.41 (t, J=5.9 Hz, 1H), 7.41 (m, 1H), 7.24 (d, 
J=7.8 Hz, 1H), 7.19 (bs, 2H), 4.27 (d, J=6 Hz, 2H), 2.38 (m, 4H). 13C NMR (DMSO-d6, 100 
MHz) δ 174.38, 171.79, 148.98, 143.21, 130.67, 126.63, 120.47 (q, J=254.6 Hz), 119.96, 119.63, 
41.97, 30.45, 29.57; HRMS, DART calcd. for C12H12F3NO4 [M+H+] 292.07966, found: 
292.08099. 
 
N1-(2-oxo-2-(pyrrolidin-1-yl)ethyl)-N4-(3-(trifluoromethoxy)benzyl)succinamide (CDE-
504): To a solution of CDE-503 (95.6 mg, 0.328 mmol) in 6 mL CH2Cl2, 2-amino-1-pyrrolidin-
1-yl-ethanone hydrochloride (108.4 mg, 0.658 mmol), DMF (0.6 mL), HOBt · H2O (61.6 mg, 
0.455 mmol), N-methylmorpholine (0.072 mL, 0.655 mmol) were added with stirring in an ice 
bath, followed by the addition of EDC · HCl (75.7 mg, 0.395 mmol). The reaction mixture was 
allowed to stir overnight. The stir bar was then removed and solvent was evaporated. A solution 
of 4:1 EtOAc:hexanes (30 mL) was then added and transferred to a separatory funnel, leaving a 
yellow oil behind. The organic layer was washed with 2 × 25 mL 0.1N NaOH and 2 × 25 mL 
brine, dried with anhydrous MgSO4, filtered, and concentrated to give 67.9 mg (51.8%) of CDE-
504 as a white, granular solid. 1H NMR (DMSO-d6, 400 MHz) δ 8.39 (t, J=6 Hz, 1H), 7.94 (t, 
J=5.5 Hz, 1H), 7.39 (t, J=8.7 Hz, 1H), 7.24 (d, J=7.8 Hz, 1H), 7.19 (s, 2H), 4.26 (d, J=6 Hz, 2H), 
3.79 (d, J=5.5 Hz, 2H), 3.34 (m, 2H), 3.25 (m, 2H), 2.38 (m, 4H), 1.78 (m, 4H). 13C NMR 
(DMSO-d6, 100 MHz) δ 172.11, 171.99, 148.99, 143.22, 130.67, 126.66, 120.52 (q, J=254.6 
Hz), 119.99, 119.61, 46.04, 45.44, 41.97, 41.79, 31.27, 31.02, 26.14, 24.22; HRMS, DART 
calcd. for C18H22F3N3O4 [M+H+] 402.16408, found: 402.16199. 
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N1-(2-morpholino-2-oxoethyl)-N4-(3-(trifluoromethoxy)benzyl)succinamide (CDE-505): To 
a solution of CDE-503 (100.9 mg, 0.347 mmol) in 6.1 mL CH2Cl2, 2-amino-1-morpholino-1-
ethanone hydrochloride (125.1 mg, 0.693 mmol), DMF (0.5 mL), HOBt · H2O (58.8 mg, 0.435 
mmol), N-methylmorpholine (0.076 mL, 0.691 mmol) were added with stirring in an ice bath, 
followed by the addition of EDC · HCl (80.5 mg, 0.420 mmol). The reaction mixture was 
allowed to stir overnight. The stir bar was then removed and solvent was evaporated. A solution 
of 4:1 EtOAc:hexanes (30mL) was then added and transferred to a separatory funnel, leaving a 
yellow oil behind. The organic layer was washed with 2 × 25 mL 0.1N NaOH and 2 × 25 mL 
brine, dried with anhydrous MgSO4, filtered, and concentrated to give 62.2 mg (43.2%) of CDE-
505 as a white solid. 1H NMR (DMSO-d6, 400 MHz) δ 8.39 (t, J=5.5 Hz, 1H), 7.95 (t, J=5 Hz, 
1H), 7.41 (t, J=7.8 Hz, 1H), 7.24 (d, J=7.3 Hz, 1H), 7.19 (bs, 2H), 4.26 (d, J=6 Hz, 2H), 3.89 (d, 
J=5.5 Hz, 2H), 3.51 (bs, 4H), 3.81 (bs, 4H). 13C NMR (DMSO-d6, 100 MHz) δ 172.09, 172.00, 
167.78, 148.98, 143.22, 130.68, 126.66, 120.75 (q, J=254.6), 119.99, 119.63, 66.51 (d, J=6.7 
Hz), 45.08, 40.65, 40.45, 31.21, 31.03; HRMS, DART calcd. for C18H22F3N3O5 [M+H+] 
418.15898, found: 418.15302. 
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N1-(3-(trifluoromethoxy)benzyl)succinamide (CDE-506): 124.2 mg (0.407 mmol) of CDE-
501 was added to a reaction vial with a stir bar followed by the dropwise addition of ammonia in 
methanol (4.0 mL, 181.0 mmol, 7 N). The solution was allowed to react overnight. TLC in 50:50 
EtOAc:hexanes the next day showed that not all starting material had been consumed and 
therefore more ammonia in methanol (2 mL, 90.0 mmol, 7 N) as well as ethanol (0.5 mL) was 
added and allowed to react overnight. The solution was then rotovapped and the resulting solid 
was triturated with chloroform to produce 44.0 mg (37.3%) of CDE-506 as a white, granular 
solid. 1H NMR (DMSO-d6, 400 MHz) δ 8.38 (t, J=5.9 Hz, 1H), 7.39 (m, 1H), 7.24 (d, J=7.8 Hz, 
2H), 7.19 (s, 2H), 6.69 (s, 1H), 4.26 (d, J=6 Hz, 2H), 2.31 (m, 4H). 13C NMR (DMSO-d6, 100 
MHz) δ 173.91, 172.25, 148.97, 143.27, 130.68, 126.64, 121.20 (q, J=254.6 Hz), 119.97, 119.62, 
41.95, 31.04, 30.84; HRMS, DART calcd. for C12H13F3N2O3 [M+H+] 291.09565, found: 
291.09601. 
 
Methyl 3-oxo-3-((3-(trifluoromethoxy)benzyl)amino)propanoate (CDE-509): To a solution 
of 3-trifluoromethoxy)benzylamine (1.03 mL, 7.22 mmol), pyridine (1.16 mL, 14.44 mmol), and 
CH2Cl2 (20.5 mL) stirring in an ice bath, methyl malonyl chloride (0.812 mL, 7.58 mmol) was 
added dropwise. The solution noticeably changed vibrant colors, from neon orange to yellow, 
back to orange, upon the addition of methyl malonyl chloride. The reaction was allowed to stir, 
warming to room temp, for 24 hours. The CH2Cl2 was then evaporated and the remainder diluted 
with ethyl acetate (40 mL). The solution was then washed with 3 × 25 mL 0.2N HCl and 3 × 25 
mL sat. NaHCO3, dried with anhydrous MgSO4, filtered and concentrated to provide 1.8915 g 
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(90.0%) of crude material. Column chromatography was performed using a gradient of 20%, 
40%, and 75% EtOAc:hexanes as the eluent to give 602.8 mg (28.7%) of CDE-509 as a powdery 
white solid. TLC confirmed CDE-509 to have an r.f. of 0.4 in 75% EtOAc:hexanes. 1H NMR 
(CDCl3, 400 MHz) δ 7.53 (bs, 1H), 7.35 (t, J=7.8 Hz, 1H), 7.21 (d, J=7.8 Hz, 1H), 7.13 (s, 1H), 
7.11 (bs, 1H), 4.5 (d, J=6 Hz, 2H), 3.74 (s, 3H), 3.38 (s, 2H). 13C NMR (DMSO-d6, 100 MHz) δ 
170.09, 165.03, 149.57, 140.41, 130.16, 125.98, 120.80 (q, J=255.5 Hz), 120.17, 119.95, 52.61 
(m), 42.98, 40.79; HRMS, DART calcd. for C12H12F3NO4 [M+H+] 292.07966, found: 
292.07599. 
 
 
3-hydrazinyl-3-oxo-N-(3-(trifluoromethoxy)benzyl)propanamide (CDE-511): 73.5 mg 
(0.253 mmol) of CDE-509 was dissolved in EtOH (2 mL) and hydrazine hydrate (0.128 mL, 
1.012 mmol, ~50% in H2O) was added. The reaction was monitored by TLC and after 8 hours all 
starting material had been consumed. The solution was rotovapped and concentrated to give 67.9 
mg (92.3%) of CDE-511 as a white solid. 1H NMR (DMSO-d6, 400 MHz) δ 9.09 (bs, 1H), 8.52 
(t, J=6 Hz, 1H), 7.42 (t, J=7.8 Hz, 1H), 7.29 (d, J=7.3 Hz, 1H), 7.23 (s, 1H), 7.21 (d, J=7.8 Hz, 
1H), 4.29 (d, J=5.9 Hz, 2H), 4.22 (bs, 2H), 3.00 (s, 2H). 13C NMR (DMSO-d6, 100 MHz) δ 
167.35, 166.71, 148.99, 142.84, 130.70, 126.69, 120.40 (q, J=254.6 Hz), 120.06, 119.71, 42.28, 
42.13; HRMS, DART calcd. for C11H12F3N3O3 [M+H+] 292.09089, found: 292.09201. 
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(Z)-methyl 3-(3,4-dimethoxyphenyl)-2-((3-(trifluoromethoxy)benzyl)carbamoyl)acrylate 
(CDE-512): CDE-509 (74.4 mg, 0.256 mmol), veratraldehyde (214.8 mg, 1.28 mmol), and 
piperidine (0.006 mL, 0.064 mmol) were placed in a microwave tube and subjected to irradiation 
for 7.5 minutes at 100 ºC at 250W. The solution was then diluted with EtOAc (30 mL) and 
washed with 2 × 25 mL 0.1N HCl. The solution was then concentrated to give 265.2 mg (100%) 
of crude material. The material was then subjected to column chromatography with 40% 
EtOAc:hexanes as the eluent. 133.9 mg (100%) of crude material was recovered from the 
column and triturated with hexanes to yield 30.8 mg (27.4%) of CDE-512 as a white crystalline 
solid. 1H NMR (CDCl3, 400 MHz) δ  7.71 (s, 1H), 7.32 (t, J=7.8 Hz, 1H), 7.2 (d, J=7.8 Hz, 1H), 
7.14 (bs, 3H), 7.11 (d, J=2.3 Hz, 1H), 6.8 (d, J=9.2 Hz, 1H), 6.19 (t, J=5.9 Hz, 1H), 4.59 (d, 
J=6.4 Hz, 2H), 3.90 (s, 3H), 3.84 (s, 3H), 3.79 (s, 3H). 13C NMR (CDCl3, 100 MHz) δ 166.84, 
165.66, 151.45, 149.57, 148.99, 143.00, 140.07, 130.11, 126.04, 125.76, 125.58, 124.60, 120.27 
(q, J=256.5 Hz), 120.25, 119.99, 112.30, 110.96, 55.98, 55.87, 52.59, 43.08; HRMS, DART 
calcd. for C21H20F3NO6 [M+H+] 440.13209, found: 440.12799. 
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3-oxo-3-((3-(trifluoromethoxy)benzyl)amino)propanoic acid (CDE-521): CDE-509  (332.0 
mg, 1.140 mmol) was dissolved in EtOH (6.90 mL) with stirring in an ice bath. 5M NaOH (0.92 
mL, 4.562 mmol) was added dropwise and the reaction was allowed to proceed overnight at 
room temperature. The solution was diluted with chilled 30 mL CH2Cl2 and washed 2 × 25 mL 
chilled 0.2N HCl and 2 × 25 mL chilled brine. The organic layers were then dried with 
anhydrous MgSO4, filtered and concentrated via rotovap at low heat to give 197.0 mg (62.3%) of 
CDE-521 as an off-white brittle solid. 1H NMR (DMSO-d6, 400 MHz) δ 8.61 (t, J=6 Hz, 1H), 
7.42 (t, J=7.8 Hz, 1H), 7.27 (m, 2H), 7.23 (d, J=6 Hz, 1H), 4.31 (d, J=6 Hz, 2H), 3.18 (s, 2H). 
13C NMR (DMSO-d6, 100 MHz) δ 170.04, 166.53, 149.02, 142.76, 130.70, 126.67, 120.61 (q, J= 
254 Hz), 120.00, 119.77, 43.19, 42.06; HRMS, DART calcd. for C11H10F3NO4 [M+H+] 
278.06401, found: 278.06601.  
 
N1-(2-oxo-2-(pyrrolidin-1-yl)ethyl)-N3-(3-(trifluoromethoxy)benzyl)malonamide (CDE-
522): To a solution of CDE-521 (68.5 mg, 0.250 mmol) in 7.5 mL CH2Cl2, 2-amino-1-
pyrrolidin-1-yl-ethanone hydrochloride (85.7 mg, 0.500 mmol), DMF (0.51 mL), HOBt · H2O 
(49.0 mg, 0.300 mmol), N-methylmorpholine (0.0550 mL, 0.500 mmol) were added with stirring 
in an ice bath, followed by the addition of EDC · HCl (53.8 mg, 0.300 mmol). The reaction 
mixture was allowed to stir overnight. The stir bar was then removed and solvent was 
evaporated. A solution of 4:1 EtOAc:hexanes (30 mL) was then added and transferred to a 
separatory funnel, leaving a yellow viscous material behind. The organic layer was washed with 
2 × 25 mL 0.2N NaOH and 2 × 25 mL brine, dried with anhydrous MgSO4, filtered, and 
58 
 
concentrated. The off-white crystalline solid was then triturated with hexanes to give 31.9 mg 
(33.2%) of CDE-522 as a white powdery solid. 1H NMR (CDCl3, 400 MHz) δ 7.86 (bs, 1H), 
7.34 (t, J=7.8 Hz, 1H), 7.23 (d, J=7.8 Hz, 1H), 7.10 (m, 3H), 4.47 (d, J=6 Hz, 2H), 3.97 (d, J=4.1 
Hz, 2H), 3.49 (t, J=6.9 Hz, 2H), 3.37 (t, J=6.4 Hz, 2H), 3.31 (s, 2H), 1.93 (m, 4H). 13C NMR 
(CDCl3, 100 MHz) δ 168.12, 166.46, 165.93, 149.50, 140.67, 130.06, 126.03, 120.51 (q, J=255 
Hz), 120.21, 119.76, 46.19, 45.60, 26.00, 24.20; HRMS, DART calcd. for C17H20F3N3O4 
[M+H+] 388.14842, found: 388.14401.  
 
 
N1-(2-morpholino-2-oxoethyl)-N3-(3-(trifluoromethoxy)benzyl)malonamide (CDE-523):  
To a solution of CDE-521 (82.0 mg, 0.300 mmol) in 6.0 mL CH2Cl2, 2-amino-1-morpholino-1-
ethanone hydrochloride (109.2 mg, 0.600 mmol), DMF (0.50 mL), HOBt · H2O (55.3 mg, 0.360 
mmol), N-methylmorpholine (0.0660 mL, 0.600 mmol) were added with stirring in an ice bath, 
followed by the addition of EDC · HCl (68.7 mg, 0.360 mmol). The reaction mixture was 
allowed to stir overnight. The stir bar was then removed and solvent was evaporated. A solution 
of 4:1 EtOAc:hexanes (30 mL) was then added and transferred to a separatory funnel, leaving a 
yellow viscous material behind. The organic layer was washed with 2 × 25 mL 0.2N NaOH and 
2 × 25 mL brine, dried with anhydrous MgSO4, filtered, and concentrated. The white solid was 
then triturated with hexanes to give 57.1 mg (47.2%) of CDE-523 as a white solid. 1H NMR 
(CDCl3, 400 MHz) δ 7.63 (bs, 1H), 7.34 (t, J=7.4 Hz, 1H), 7.21 (d, J=7.8 Hz, 1H), 7.17 (bs, 1H), 
7.12 (bs, 1H), 7.10 (bs, 1H), 4.49 (d, J=6 Hz, 2H), 4.05 (d, J=4.1 Hz, 2H), 3.67 (m, 6H), 3.39 (t, 
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J=5.0 Hz, 2H), 3.30 (s, 2H) 13C NMR (CDCl3, 100 MHz) δ 167.94, 166.51, 166.24, 149.50, 
140.47, 130.09, 126.03, 120.50 (q, J=255 Hz), 120.17, 119.82, 66.67, 66.35, 44.93, 42.93, 42.75, 
42.42, 41.30; HRMS, DART calcd. for C17H20F3N3O5 [M+H+] 404.14332, found: 404.14099. 
 
 
 
N1-(3-(trifluoromethoxy)benzyl)malonamide (CDE-524): CDE-509 (71.4 mg, 0.245 mmol) 
was dissolved in ammonia in methanol (28.1 mL, 1273 mmol, 7 N) in an ice bath and stirred for 
3.5 hours. The vial was then moved to cold storage for an additional 9 hours at which time the 
solution was tested via TLC using 1:1 EtOAc:hexanes to verify all starting material had been 
consumed and no side products were produced. The solvent was evaporated and the solution 
concentrated to give 52.0 mg (77.6%) of CDE-524 as a green-tinted tacky solid. 1H NMR 
(CDCl3, 400 MHz) δ 7.63 (bs, 1H), 7.32 (t, J=8.2 Hz, 1H), 7.25 (s, 1H), 7.17 (d, J=7.8 Hz, 1H), 
7.11 (s, 1H), 7.00 (bs, 1H), 5.80 (bs, 1H), 4.43 (d, J=17 Hz, 2H), 3.24 (s, 2H). 13C NMR 
(CDCl3, 100 MHz) δ 169.88, 167.27, 149.55, 140.26, 130.16, 125.89, 120.51 (q, J=255 Hz), 
120.11, 119.96, 43.03, 42.68; HRMS, DART calcd. for C11H11F3N2O3 [M+H+] 277.08000, 
found: 277.07901. 
 
 
 
 
